# Lapatinib ditosylate

## Tykerb 250mg

##### 臨採

| TAH Drug Code      | [**OTYK**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OTYK)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | In combination w/ capecitabine for the treatment of patients w/ advanced/metastatic breast cancer whose tumours overexpress HER2 & who have received prior therapy including anthracycline, taxane & trastuzumab. In combination w/ letrozole for the treatment of post-menopausal women w/ hormone receptor positive metastatic breast cancer that overexpress HER2 receptor for whom hormonal therapy is indicated.                                                                                                                                                                    |
| Dosing             | Monitor left ventricular ejection fraction (baseline and periodic) before and during therapy. TYKERB should be taken at least one hour before or one hour after a meal. [Advanced/metastatic breast cancer] 1250 mg (5 tablets) once daily on Days 1-21 continuously in combination with capecitabine 2,000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. [Hormone receptor ( + ), HER2 ( + ) metastatic breast cancer] 1500 mg (6 tablets) once daily continuously in combination with letrozole 2.5 mg once daily. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to lapatinib ditosylate or to any of the excipients of Tykerb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Anorexia, diarrhea, nausea, vomiting, rash, fatigue, dyspepsia, dry skin, stomatitis, constipation, abdominal pain, palmar-plantar erythrodysesthesia, mucosal inflammation, pain in extremity, back pain, insomnia, epistaxis, alopecia; decreased LVEF, nail disorders, headache.                                                                                                                                                                                                                                                                                                      |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

